Dr Reddy’s Q1FY24 Results: Consolidated PAT Rises to Rs. 1402.5 Cr

Dr Reddy's Q2 FY24 Results: Consolidated PAT Rises to Rs. 1482.2 Cr

Dr Reddy’s Q1 results show revenue up from 6296.8 crores to 6738.4 crores, a 7.01% increase in growth. EPS rise from ₹57.62 to ₹84.22, up by 46.16%.

First, Let’s Begin with Quarter-on-Quarter Basis:

Dr Reddy’s shared its Q1 results on Wednesday. They earned 6738.4 crores in revenue this quarter, but that’s more than the 6296.8 crores they made last quarter. The company’s growth increased by 7.01 percent when comparing the two quarters.

In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 1402.5 crores, up from 959.2 crores in the previous quarter. Their quarter-to-quarter growth increased by 46.22 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹84.22, which is an increase of 46.16% from the ₹57.62 EPS in the previous quarter.

Now, Let’s Analyze the Results on a Year-over-Year Basis:

The company made a total revenue of 6738.4 crores this year (2023), which is 29.20 percent higher than last year’s total revenue of 5215.4 crores.

This year’s PAT (Profit After Tax) is 1402.5 crores, which is also 18.10% higher than last year’s PAT of 1187.6 crores.

The EPS (Earnings Per Share) for this year is ₹84.22, which is 17.96% more than the EPS of ₹71.40 earned last year.

Dr Reddy’s Share Dividend Announcement / Record Date:

The record date for the dividend has not arrived yet.

About Dr Reddy’s Laboratories:

Dr Reddy’s Laboratories is a Hyderabad-based Indian multinational pharmaceutical company. It was founded by Kallam Anji Reddy, who had previously worked at the mentor institute Indian Drugs and Pharmaceuticals Limited.

Download the Full PDF of Dr Reddy’s Q1 Results: Click Here

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *